in4thelonghaul

Why Orexigen's Empatic News Is Good

Phase II means nothing in regards to competitors P-3 results. VVUS has by far the most effective candidate. Didn't almost 50% of ARNA's Contrave trial participants drop out?


Most informed patients will demand VVUS's Qnexa, and most will be willing to chance dry mouth, and possible tingling in the fingers to achieve the benefits of 15% weight loss which isn't gained back immediateely after they stop taking it. Seems likely that most insurance companies will favor Qnexa as well...why shell out so much money for a years worth of Lorcaserin, when Qnexa is 3 times more effective and has positive effects on blood pressure, blood sugar and triglycerides?

Almost certainly, physicians will first prescribe Qnexa, then Lorcaserin for those who decide they don't like the side effects. Only proiblem is Lorcaserin barely works, so many who get that will quit taking it after a couple o0f months and will go back to Qnexa, or might then try Contrave. But how many who take Contrave will be willing to endure nausea and headaches..not many.

VVUS's Qnexa will be a $ 3 billion blockbuster in the U.S. alone, and the clear winner in this race; then there is the potential for specific use for those with diabetes, and they do have a potential winner in their ED candidate...results soon to be out.